



A Pfizer Company

SAFETY DATA SHEET

Revision date: 29-Jul-2016

Version: 1.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Labetalol Hydrochloride Injection, USP (Hospira Inc.)

Trade Name: Labetalol Hydrochloride Injection, USP

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as cardiovascular drug

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

Label Elements

Signal Word: Warning

Hazard Statements: H361f - Suspected of damaging fertility

Precautionary Statements:

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 2 of 9

Version: 1.0



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Labetalol Hydrochloride	32780-64-6	251-211-1	Repr 2 (H361f)	0.5
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*
Dextrose	14431-43-7	Not Listed	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*
Citric acid monohydrate	5949-29-1	Not Listed	Not Listed	**
Propylparaben	94-13-3	202-307-7	Not Listed	*
Edetate disodium	139-33-3	205-358-3	Not Listed	*

Additional Information:

* Proprietary
** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

- Eye Contact:** Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.
- Skin Contact:** Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 3 of 9

Version: 1.0

Inhalation: Move to fresh air If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Incompatible Materials: None known

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 4 of 9

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Labetalol Hydrochloride

Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 5 of 9

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Colorless to light yellow
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	Soluble
pH:	3.0-4.5
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Water for Injection

No data available

Dextrose

No data available

Methylparaben

No data available

Propylparaben

No data available

Citric acid monohydrate

No data available

SODIUM HYDROXIDE

No data available

Edetate disodium

No data available

Labetalol Hydrochloride

No data available

Decomposition Temperature (°C):	No data available.
--	--------------------

Evaporation Rate (Gram/s):	No data available
-----------------------------------	-------------------

Vapor Pressure (kPa):	No data available
------------------------------	-------------------

Vapor Density (g/ml):	No data available
------------------------------	-------------------

Relative Density:	No data available
--------------------------	-------------------

Viscosity:	No data available
-------------------	-------------------

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
---	-------------------

Flammability (Solids):	No data available
-------------------------------	-------------------

Flash Point (Liquid) (°C):	No data available
-----------------------------------	-------------------

Upper Explosive Limits (Liquid) (% by Vol.):	No data available
---	-------------------

Lower Explosive Limits (Liquid) (% by Vol.):	No data available
---	-------------------

10. STABILITY AND REACTIVITY

Reactivity:	No data available
--------------------	-------------------

Chemical Stability:	Stable under normal conditions of use.
----------------------------	--

Possibility of Hazardous Reactions

Oxidizing Properties:	None
------------------------------	------

Conditions to Avoid:	None known
-----------------------------	------------

Incompatible Materials:	None known
--------------------------------	------------

Hazardous Decomposition Products:	None known
--	------------

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 6 of 9

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Known Clinical Effects:

The most common adverse effects seen during clinical use of this drug include nausea, vomiting, shortness of breath (dyspnea), fatigue, low blood pressure on standing (orthostatic hypotension), abnormal ejaculation, impotence.

Acute Toxicity: (Species, Route, End Point, Dose)

Propylparaben

Mouse Oral LD 50 6332 mg/kg
Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Labetalol Hydrochloride

Rat Oral LD50 2114 mg/kg
Mouse Oral LD50 600mg/kg
Rabbit Oral LD50 1250mg/kg
Rat Intravenous LD50 53mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid monohydrate

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system
4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Labetalol Hydrochloride

Reproductive & Fertility Rat Oral 50 mg/kg/day LOAEL Fertility
Embryo / Fetal Development Rat Oral 125 mg/kg/day NOAEL Not Teratogenic, Embryotoxicity
Embryo / Fetal Development Rabbit Oral 4 times human dose NOAEL Not Teratogenic

Reproductive Effects

Adverse reproductive effects were observed in human males during therapeutic use.

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Labetalol Hydrochloride

Bacterial Mutagenicity (Ames) Bacteria Negative
Dominant Lethal Assay Rat Negative
Dominant Lethal Assay Mouse Negative

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 7 of 9

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Labetalol Hydrochloride

18 Month(s) Mouse Oral 200 mg/kg/day NOAEL Not carcinogenic
113-116 Week(s) Rat Oral 225 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 8 of 9

Version: 1.0

15. REGULATORY INFORMATION

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Labetalol Hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	251-211-1

Dextrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

Citric acid monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

Propylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Labetalol Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016

Page 9 of 9

Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-307-7

Edetate disodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	205-358-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Reproductive toxicity-Cat.2; H361f - Suspected of damaging fertility

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 29-Jul-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet